Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
15
ICCM Quote, Financials, Valuation and Earnings
Last price:
$0.29
Seasonality move
:
25.42%
Day range:
$0.28 - $0.31
52-week range:
$0.28 - $1.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.70x
P/B ratio:
2.69x
Volume:
524.7K
Avg. volume:
633.1K
1-year change:
-75.81%
Market cap:
$23.7M
Revenue:
$3.4M
EPS (TTM):
-$0.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
$1.5M | -$0.03 | 101.59% | -50.9% | $2.73 |
|
BLRX
BioLineRx Ltd.
|
$343K | -$1.04 | 35.2% | -49.07% | $20.33 |
|
CGEN
Compugen Ltd.
|
$1.2M | -$0.08 | -46.52% | -2.83% | $5.80 |
|
ENTX
Entera Bio Ltd.
|
-- | -- | -100% | -- | $10.00 |
|
PLUR
Pluri, Inc.
|
$638K | -$0.65 | 316.67% | -79.86% | $12.00 |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
$0.30 | $2.73 | $23.7M | -- | $0.00 | 0% | 5.70x |
|
BLRX
BioLineRx Ltd.
|
$2.21 | $20.33 | $10M | -- | $0.00 | 0% | 7.60x |
|
CGEN
Compugen Ltd.
|
$2.26 | $5.80 | $220M | 6.30x | $0.00 | 0% | 2.99x |
|
ENTX
Entera Bio Ltd.
|
$1.26 | $10.00 | $63.9M | -- | $0.00 | 0% | 1,376.12x |
|
PLUR
Pluri, Inc.
|
$3.32 | $12.00 | $33.4M | -- | $0.00 | 0% | 20.28x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
$2.43 | -- | $5.7M | -- | $0.00 | 0% | 34.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
2.34% | 1.866 | 0.49% | 1.91x |
|
BLRX
BioLineRx Ltd.
|
35.81% | 3.203 | 59% | 1.73x |
|
CGEN
Compugen Ltd.
|
2.8% | -0.650 | 2.05% | 6.45x |
|
ENTX
Entera Bio Ltd.
|
3.61% | 1.015 | 0.55% | 6.76x |
|
PLUR
Pluri, Inc.
|
172.93% | -0.001 | 98.32% | 0.40x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
2.86% | 0.921 | 1.28% | 0.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd.
|
$600K | -$4.2M | -198.84% | -220.46% | -329.63% | -$5.5M |
|
BLRX
BioLineRx Ltd.
|
$91.6K | -$3.4M | -6.72% | -11.07% | -1745.49% | -$3.3M |
|
CGEN
Compugen Ltd.
|
$63.8M | $56M | 54.64% | 57.22% | 83.23% | -- |
|
ENTX
Entera Bio Ltd.
|
-$7K | -$3M | -76.83% | -78.3% | -6102.38% | -$2.1M |
|
PLUR
Pluri, Inc.
|
-$43K | -$6.5M | -93.31% | -5662.45% | -3285.86% | -$5.7M |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -$764K | -33.97% | -34.34% | -283.95% | -- |
IceCure Medical Ltd. vs. Competitors
-
Which has Higher Returns ICCM or BLRX?
BioLineRx Ltd. has a net margin of -331.98% compared to IceCure Medical Ltd.'s net margin of -1152.66%. IceCure Medical Ltd.'s return on equity of -220.46% beat BioLineRx Ltd.'s return on equity of -11.07%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.46.91% -$0.06 $9.3M BLRXBioLineRx Ltd.46.93% -$0.32 $33.5M -
What do Analysts Say About ICCM or BLRX?
IceCure Medical Ltd. has a consensus price target of $2.73, signalling upside risk potential of 808.33%. On the other hand BioLineRx Ltd. has an analysts' consensus of $20.33 which suggests that it could grow by 820.06%. Given that BioLineRx Ltd. has higher upside potential than IceCure Medical Ltd., analysts believe BioLineRx Ltd. is more attractive than IceCure Medical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 BLRXBioLineRx Ltd.2 0 0 -
Is ICCM or BLRX More Risky?
IceCure Medical Ltd. has a beta of 1.104, which suggesting that the stock is 10.35% more volatile than S&P 500. In comparison BioLineRx Ltd. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.372%.
-
Which is a Better Dividend Stock ICCM or BLRX?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLineRx Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. BioLineRx Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or BLRX?
IceCure Medical Ltd. quarterly revenues are $1.3M, which are larger than BioLineRx Ltd. quarterly revenues of $195.2K. IceCure Medical Ltd.'s net income of -$4.2M is lower than BioLineRx Ltd.'s net income of -$2.3M. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while BioLineRx Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 5.70x versus 7.60x for BioLineRx Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.5.70x -- $1.3M -$4.2M BLRXBioLineRx Ltd.7.60x -- $195.2K -$2.3M
-
Which has Higher Returns ICCM or CGEN?
Compugen Ltd. has a net margin of -331.98% compared to IceCure Medical Ltd.'s net margin of 84.43%. IceCure Medical Ltd.'s return on equity of -220.46% beat Compugen Ltd.'s return on equity of 57.22%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.46.91% -$0.06 $9.3M CGENCompugen Ltd.94.75% $0.60 $105.7M -
What do Analysts Say About ICCM or CGEN?
IceCure Medical Ltd. has a consensus price target of $2.73, signalling upside risk potential of 808.33%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 156.64%. Given that IceCure Medical Ltd. has higher upside potential than Compugen Ltd., analysts believe IceCure Medical Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 CGENCompugen Ltd.5 0 0 -
Is ICCM or CGEN More Risky?
IceCure Medical Ltd. has a beta of 1.104, which suggesting that the stock is 10.35% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.766, suggesting its more volatile than the S&P 500 by 176.625%.
-
Which is a Better Dividend Stock ICCM or CGEN?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or CGEN?
IceCure Medical Ltd. quarterly revenues are $1.3M, which are smaller than Compugen Ltd. quarterly revenues of $67.3M. IceCure Medical Ltd.'s net income of -$4.2M is lower than Compugen Ltd.'s net income of $56.8M. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 6.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 5.70x versus 2.99x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.5.70x -- $1.3M -$4.2M CGENCompugen Ltd.2.99x 6.30x $67.3M $56.8M
-
Which has Higher Returns ICCM or ENTX?
Entera Bio Ltd. has a net margin of -331.98% compared to IceCure Medical Ltd.'s net margin of -6111.91%. IceCure Medical Ltd.'s return on equity of -220.46% beat Entera Bio Ltd.'s return on equity of -78.3%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.46.91% -$0.06 $9.3M ENTXEntera Bio Ltd.-- -$0.07 $13.6M -
What do Analysts Say About ICCM or ENTX?
IceCure Medical Ltd. has a consensus price target of $2.73, signalling upside risk potential of 808.33%. On the other hand Entera Bio Ltd. has an analysts' consensus of $10.00 which suggests that it could grow by 693.65%. Given that IceCure Medical Ltd. has higher upside potential than Entera Bio Ltd., analysts believe IceCure Medical Ltd. is more attractive than Entera Bio Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 ENTXEntera Bio Ltd.1 0 0 -
Is ICCM or ENTX More Risky?
IceCure Medical Ltd. has a beta of 1.104, which suggesting that the stock is 10.35% more volatile than S&P 500. In comparison Entera Bio Ltd. has a beta of 1.538, suggesting its more volatile than the S&P 500 by 53.812%.
-
Which is a Better Dividend Stock ICCM or ENTX?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entera Bio Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Entera Bio Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or ENTX?
IceCure Medical Ltd. quarterly revenues are $1.3M, which are larger than Entera Bio Ltd. quarterly revenues of --. IceCure Medical Ltd.'s net income of -$4.2M is lower than Entera Bio Ltd.'s net income of -$3M. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Entera Bio Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 5.70x versus 1,376.12x for Entera Bio Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.5.70x -- $1.3M -$4.2M ENTXEntera Bio Ltd.1,376.12x -- -- -$3M
-
Which has Higher Returns ICCM or PLUR?
Pluri, Inc. has a net margin of -331.98% compared to IceCure Medical Ltd.'s net margin of -3470.71%. IceCure Medical Ltd.'s return on equity of -220.46% beat Pluri, Inc.'s return on equity of -5662.45%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.46.91% -$0.06 $9.3M PLURPluri, Inc.-21.72% -$0.71 $25.4M -
What do Analysts Say About ICCM or PLUR?
IceCure Medical Ltd. has a consensus price target of $2.73, signalling upside risk potential of 808.33%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 261.45%. Given that IceCure Medical Ltd. has higher upside potential than Pluri, Inc., analysts believe IceCure Medical Ltd. is more attractive than Pluri, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 PLURPluri, Inc.1 0 0 -
Is ICCM or PLUR More Risky?
IceCure Medical Ltd. has a beta of 1.104, which suggesting that the stock is 10.35% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.767%.
-
Which is a Better Dividend Stock ICCM or PLUR?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or PLUR?
IceCure Medical Ltd. quarterly revenues are $1.3M, which are larger than Pluri, Inc. quarterly revenues of $198K. IceCure Medical Ltd.'s net income of -$4.2M is higher than Pluri, Inc.'s net income of -$6.9M. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 5.70x versus 20.28x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.5.70x -- $1.3M -$4.2M PLURPluri, Inc.20.28x -- $198K -$6.9M
-
Which has Higher Returns ICCM or XTLB?
XTL Biopharmaceuticals Ltd. has a net margin of -331.98% compared to IceCure Medical Ltd.'s net margin of -341.36%. IceCure Medical Ltd.'s return on equity of -220.46% beat XTL Biopharmaceuticals Ltd.'s return on equity of -34.34%.
Company Gross Margin Earnings Per Share Invested Capital ICCMIceCure Medical Ltd.46.91% -$0.06 $9.3M XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M -
What do Analysts Say About ICCM or XTLB?
IceCure Medical Ltd. has a consensus price target of $2.73, signalling upside risk potential of 808.33%. On the other hand XTL Biopharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could grow by 5048.45%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than IceCure Medical Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than IceCure Medical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ICCMIceCure Medical Ltd.1 0 0 XTLBXTL Biopharmaceuticals Ltd.0 0 0 -
Is ICCM or XTLB More Risky?
IceCure Medical Ltd. has a beta of 1.104, which suggesting that the stock is 10.35% more volatile than S&P 500. In comparison XTL Biopharmaceuticals Ltd. has a beta of 1.270, suggesting its more volatile than the S&P 500 by 27.027%.
-
Which is a Better Dividend Stock ICCM or XTLB?
IceCure Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IceCure Medical Ltd. pays -- of its earnings as a dividend. XTL Biopharmaceuticals Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCM or XTLB?
IceCure Medical Ltd. quarterly revenues are $1.3M, which are larger than XTL Biopharmaceuticals Ltd. quarterly revenues of $162K. IceCure Medical Ltd.'s net income of -$4.2M is lower than XTL Biopharmaceuticals Ltd.'s net income of -$553K. Notably, IceCure Medical Ltd.'s price-to-earnings ratio is -- while XTL Biopharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IceCure Medical Ltd. is 5.70x versus 34.33x for XTL Biopharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCMIceCure Medical Ltd.5.70x -- $1.3M -$4.2M XTLBXTL Biopharmaceuticals Ltd.34.33x -- $162K -$553K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
